DNSK International, LLC.

Our company is specialized in designing best-in-class clinical candidates, with exceptional safety profiles. Since 2010, we have been conducting research with leading biotechs and universities around the world on Innovative Discovery Projects.

Our specialty - Medicinal Chemistry and Synthetic Chemistry.

Our Mission

Help to save/improve the quality of lives of people all around the world by inventing many more High Quality Medicines!

Major areas of discovery: Oncology, immunology, virology, Stem Cells, anti-infectives, GPCRs

Advanced Projects:

1. PI3K Delta Selective Inhibitor for hematological malignancies

Project 2: TENALISIB (RP6530) is in advanced trials for the treatment of T-Cell Lymphoma.

More details at www.rhizen.com and

clinicaltrials.org

Selective c-Met Inhibitors to treat solid tumors

Presentations, Publications

 and Patents

103rd AACR National Meeting, Chicago, IL March 31-April 4, 2012.

Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Research 139, 2017, 49-58.

72nd ADA National Meeting, Philadelphia, PA; June 8-12, 2012

99th AAI National Meeting, Boston, MA; May 4-8, 2012

US 10220035  US 10072013    US 9815831

US 9777018    US 9775841

Please contact us for all your needs:

Registered Office:

52 Virginia Rail Drive

Bethany CT 06524, USA

Research Labs:

925 Sherman Avenue

NEBA Building

Hamden, CT 06515, USA

Telephone : 203-314-5637

Fax: 203-407-0703

info@dnskinternational.com

 naga@dnskinternational.com